Pharma pipeline analysis that shows where your asset will fit at launch.

Pharma pipeline analysis is the assessment of the therapies in development for a disease area and what they mean for one company's asset. The analysis, also called drug pipeline analysis, tracks trial phases, readouts and mechanisms, then judges differentiation, likely treatment shifts and the competitive pressure each pipeline asset brings. Nextyn adds interviews with KOLs and practicing physicians in the United States and Europe, so the read covers what the coming data will change in practice, not only what is in development.

A Nextyn pipeline and asset intelligence study delivers three outputs: a pipeline landscape for the disease area, a differentiation read on the client's asset, and KOL views on how treatment will shift. Each output combines pipeline tracking with primary interviews, not database listings alone:

• Pipeline landscape: the assets in development, their mechanisms and when their data will land
• Differentiation read: which attributes of the asset experts see as meaningful, and which they discount
• KOL view: the treatment shifts experts expect, and how confident they are in each

Nextyn interviews the three expert groups who decide how new data changes treatment: key opinion leaders, practicing specialists and, where access shapes uptake, payers. The panel is matched to the disease area and the markets in scope, so the view of the pipeline reflects the people who will use or pay for the new therapies:

• Key opinion leaders who shape guidelines and trial design
• Practicing specialists who decide treatment sequence day to day
• Payers, where coverage decides how fast new therapies reach patients

Nextyn runs pharma pipeline analysis interviews in the United States, the United Kingdom, Germany, France, Italy and Spain, among other markets. Markets are agreed at scoping and follow where the asset will launch, because treatment practice and the competitive set differ by country. Recent Nextyn work includes in-depth interviews with KOLs and practicing oncologists in France that assessed the perceived differentiation of upcoming Phase III data and the likely shifts in treatment algorithms.

Nextyn recommends pharma pipeline analysis before an asset's positioning, target product profile and development priorities are locked. At that point the read shows the treatment landscape the asset will meet at launch, not the one in place today, and there is still time to act on it. There are three other triggers for a fresh read: a major competitor readout, a new mechanism entering the disease area, and a portfolio review.

A Nextyn pipeline analysis project runs in four steps, from brief to read-out, and nothing is commissioned until the client approves the plan. The client sees the expert panel, method and price before any fieldwork, and reads every interview with the Nextyn team at the end.

1. Submit the brief: the asset, the disease area, the markets and the positioning or portfolio decision to settle.
2. Receive a plan within 48 hours: which experts Nextyn will interview, how, and what the work costs.
3. Approve the plan: fieldwork starts only after sign-off.
4. Review the read-out: every interview read together, showing where experts agree, where they conflict and what is still open.

Nextyn sends a research plan within 48 hours of receiving the brief, stating which experts will be interviewed, how, and what the work costs. The plan sets the fieldwork length for the disease area and markets in scope, and agrees the refresh schedule if the client needs ongoing tracking. Nothing is commissioned until the client approves that plan, its expert panel and its price.

Nextyn's drug pipeline analysis interprets what pipeline assets mean for one company's asset, using interviews with KOLs and physicians, while a pipeline database lists assets, mechanisms and trial status for every subscriber. The database shows what is in development, and expert interviews show which of those assets will change treatment and when.